RPGN or crescentic glomerulonephritis is a life-threatening disease that destroys kidneys over a period of days to weeks. Proliferation of epithelial cells and infiltration of inflammatory cells lead to glomerular crescent formation and disruption of the specialized microvascular network in the glomerulus. This causes hematuria, albuminuria and loss of renal function. RPGN can be associated with antibodies to glomerular basement membrane (GBM) proteins or caused by many other pathogenic mechanisms 1 , and it represents one of the few diagnostic and therapeutic emergencies in nephrology.
HB-EGF, a member of the EGF family, is expressed during inflammatory and pathological conditions. Transient expression of HB-EGF has been reported in mesangial and epithelial renal cells in an anti-GBM-serum-induced rat model of RPGN 2 . However, the evoked pathophysiological effects of HB-EGF and EGFR in this experimental RPGN model have been restricted to modulation of vasomotor tone and acute transient regulation of glomerular filtration rate and have not been reported to lead to major clinical and morphological endpoints of renal disease. Yet HB-EGF is upregulated in vascular endothelial cells by cytokines (IL-1β and TNF-α) 3 and lysophosphatidylcholine 4 , mediators that may be elicited in RPGN. Additionally, HB-EGF has been detected in conditioned medium of macrophages and macrophage-like U-937 cells 5, 6 and in CD4 + T cells within atherosclerotic plaques 7 . To our surprise, no role for HB-EGF or its tyrosine kinase receptor (EGFR) has been reported in inflammatory diseases. Studies of crescentic forms of human and experimental glomerulonephritis suggest that T cells 8, 9 and macrophages 10, 11 have important effector roles in promoting the formation of destructive cellular crescents. Therefore, we investigated whether HB-EGF is induced in an anti-GBM nephrotoxic serum (NTS)-induced mouse model of RPGN and in human renal biopsies with RPGN. We also addressed whether lack of HB-EGF or EGFR expression or pharmacological inhibition of EGFR tyrosine kinase activity could influence the course of fatal RPGN in mice.
We found that renal expression of HB-EGF was markedly upregulated after the onset of crescentic glomerulonephritis in parallel with sustained phosphorylation of EGFR in podocytes. HB-EGF-deficient mice did not show activation of EGFR in glomeruli and were markedly protected from RPGN compared with their wild-type (WT) littermates. This phenotype was recapitulated by selective deletion of the Egfr gene in podocytes. Pretreatment of animals with wild-type HB-EGF (Hbegf +/+ ) with two different EGFR tyrosine kinase inhibitors suppressed albuminuria and glomerular injury and prevented renal failure. Moreover, in addition to prophylactic treatment, therapeutic EGFR inhibition with a clinically available EGFR inhibitor effectively reduced renal damage and renal failure, even after the onset of acute renal failure. We also identified de novo production of HB-EGF protein in kidneys from humans with RPGN from various etiologies. These data demonstrate a pathophysiological role for EGFR in crescentic RPGN and suggest that inhibitors of the HB-EGF-EGFR cascade may be useful in preventing the occurrence and the progression of severe renal damage and renal failure.
RESULTS

Activation of Hbegf during crescentic glomerulonephritis
We tested for proHB-EGF mRNA by real-time RT-PCR in kidneys harvested 8 d after injection of NTS into mice. ProHB-EGF mRNA was three times more abundant in treated than control animals (proHB-EGF cDNA/18S cDNA ratio, 10.8 ± 1.7 versus 3.5 ± 1.4, respectively, n = 6, P < 0.05; data not shown). At 4 d after NTS injection and before the first appearance of crescents, we detected proHB-EGF mRNA in parietal epithelial glomerular cells and podocytes (Fig. 1a) . On day 8, we observed crescents, and in situ hybridization showed diffuse proHB-EGF mRNA labeling (Fig. 1a) . In podocytes freshly isolated by FACS, proHB-EGF mRNA was 3.6 ± 0.4-fold greater than untreated controls at 6 d after NTS injection (n = 3 per group, P < 0.05; Fig. 1b and Supplementary Methods).
Activation of EGFR during crescentic glomerulonephritis HB-EGF binds to and activates both EGFR/ErbB1 and ErbB4 receptors. We studied the phosphorylation of EGFR by immunoblot analysis of phosphorylated EGFR (pEGFR) and total EGFR with lysates extracted from renal cortex 8 d after the beginning of experimental crescentic glomerulonephritis (Fig. 1c) . Phosphorylation of EGFR was 2.6-fold greater in WT tissues after NTS injection than in nonimmunized WT or Hbegf −/− mice (n = 6, P < 0.01). Through anatomic visualization of EGFR phosphorylation by immunofluorescence, we observed strong receptor activation in glomeruli with intense pEGFR-specific staining in podocytes (Fig. 1d) that was far stronger than signals emanating from tubules. We used western blotting and immunofluorescence to demonstrate the specificity of EGFR phosphorylation in vivo in immunized mice that were injected daily with an EGFR tyrosine kinase inhibitor (AG1478) or with vehicle alone. On day 8 after NTS injection, EGFR phosphorylation remained low in the renal cortex of AG1478-treated WT mice (Fig. 1c,d) . Similarly, Hbegf −/− mice showed no increase in EGFR phosphorylation in the renal cortex on day 8 after NTS injection (Fig. 1c,d) . Together, these data demonstrate that HB-EGF has a role in EGFR phosphorylation in WT mice injected with NTS.
HB-EGF induces a migratory phenotype in podocytes in vitro
In vivo podocytes are terminally differentiated and stationary cells. During crescent formation in mice, however, podocytes assume a migratory phenotype, as they attach to the pariental basement membrane with their apical membrane and start to proliferate [12] [13] [14] . Recent data confirm that podocytes also contribute to crescents in humans 15, 16 . As an assay for podocyte crescent formation, we measured outgrowth of WT-1 + cells from isolated decapsulated mouse glomeruli. The area of podocyte outgrowth strongly depended on the presence of a functional Hbegf allele (Fig. 2a,b) . Notably, there was no gene-dose effect, (Fig. 2a,b) . In a process similar to the steps that characterize crescent formation, glomerular outgrowth of podocytes from decapsulated glomeruli involves formation of apical protrusions in podocytes, attachment and migration away from glomerular capillaries on the substrate as well as proliferation (Fig. 2c) . We assessed podocyte outgrowth in vitro by using a podocyte cell line 17 with endogenous expression of proHB-EGF mRNA (Supplementary Fig. 1a) . Applying specific inhibitors, we examined the involvement of intracellular signaling pathways in podocyte outgrowth, including the PI3 kinase pathway, which is involved in actin dynamics; the classical MAP kinase pathway, which is essential for proliferation; and the p38 MAP kinase pathway, which may be relevant for directed migration. HB-EGF caused a complete reorganization of the F-actin cytoskeleton, and massive formation of ring-like actin structures (RiLiSs) and dorsal ruffles (Fig. 2d) , indicating apically directed motility. Apical actin protrusions were completely abrogated by the PI3 kinase inhibitors wortmannin and LY294002, but they were insensitive to a highly selective inhibitor of MEK1 (PD 98059) and to a p38 MAPK inhibitor (SB 203280; Fig. 2e ). Proliferation as determined by BrdU incorporation (Supplementary Fig. 1b ) was reduced by PD 98059 in the presence of HB-EGF (Fig. 2f) . The migration rate of podocytes was doubled by addition of recombinant HB-EGF ( Fig. 2g and Supplementary Fig. 1c) , which is involved in a variety of cellular processes such as polarization, protrusion dynamics, proliferation and cell-matrix and cell-cell adhesion 18 . Inhibition of PI3 kinase, MEK1 and p38 MAPK all significantly reduced the migration rate.
The effects of HB-EGF on podocytes were mediated by EGFR, as they were blocked by AG1478 (Fig. 2d-g ). Notably, EGFR tyrosine kinase inhibition mimicked the effect of HB-EGF deficiency on glomerular outgrowth (Fig. 2a,b) indicating that EGFR/ErbB1 is a prominent, if not the only, receptor mediating podocyte proliferation and migration. Thus, HB-EGF triggers a phenotypic switch in podocytes that is required for crescent formation, and that involves multiple signaling pathways.
Attenuated RPGN and no lethal renal failure in Hbegf −/− mice Twelve Hbegf −/− and 14 WT male littermates had similar renal histology and functional parameters (microalbuminuria, serum creatinine and blood urea nitrogen (BUN)) at baseline (data not shown). Therefore, we used preimmunized but unchallenged WT mice as baseline controls, unless otherwise specified. We histologically examined WT mice injected with NTS, and found severe glomerulonephritis and reduced survival by day 8 ( Fig. 3a) , whereas Hbegf −/− littermates had significantly less renal damage (Fig. 3b) . Nephrotic syndrome is caused by hypoproteinemia due to massive urinary loss of large proteins, particularly albumin, leading to hypoalbuminemia and ascites. HB-EGF deficiency significantly prevented both the incidence and severity of ascites ( Fig. 3c) as well as renal dysfunction reflected by albuminuria ( Fig. 3d) and by BUN concentrations, which were normal in Hbegf −/− mice (Fig. 3e) . Consistent with renal protection associated with lack of HB-EGF, all Hbegf −/− animals survived, whereas 30% of WT littermates died within 8 d (P < 0.01, Fig. 3a) . In all cases, death was associated with severe renal damage with macroscopic hematuria (blood leakage into the urine), and animals died from renal failure (with 100% having crescentic and necrotizing lesions at autopsy) (data not shown).
We observed similar protective effects of HB-EGF deficiency in an independent experiment in which we followed animals for 21 d (data not shown). Fig. 2a-d) . In response to NTS, WT mice had podocytes with mild to severe effacement of foot processes and bridge formation between the parietal and glomerular basement membranes ( Supplementary Fig. 2e,f) . These ultrastructural alterations were markedly attenuated in Hbegf −/− animals ( Supplementary Fig. 2g,h ). We observed slender processes (diameter <0.1 µm) protruding into the urinary space in both groups of mice treated with NTS.
HB-EGF in the immunoinflammation associated with RPGN
Although T cells and macrophages are central players both in our mouse model of NTS-induced glomerulonephritis and in human crescentic RPGN 9, 11, 19 , antibody deposition may also have a pathophysiological role in the very early stages of the disease, promoting activation of the complement pathway 9, 20 . Therefore, we assessed the humoral response of Hbegf −/− and WT littermates to sheep IgG. Serial dilutions of sera from preimmunized animals showed similar titers of mouse anti-sheep antibodies (Supplementary Fig. 3a ) with similar patterns of IgG deposition in glomerular basement membranes in the kidneys of both groups after NTS injection (Supplementary Fig. 3b ).
Thus, we found no evidence that HB-EGF altered the humoral immune response in this model. In contrast, HB-EGF deficient mice had fewer infiltrated CD3 + T cells in and around their glomeruli than their WT counterparts after NTS administration (P < 0.01; Supplementary  Fig. 3c,d ) and fewer F4/80 + macrophages in the kidney cortex on day 8 after NTS injection (data not shown).
As HB-EGF has been found in macrophages 6 and T lymphocyte subsets 7, 21 , we sought to evaluate the potential role of nonglomerular HB-EGF in RPGN. To this end, we lethally irradiated WT control mice and reconstituted them with bone marrow from either WT or Hbegf −/− congenic mice. At 10 weeks after transfer, experimental RPGN was induced and renal histology and function were determined 14 d later. Notably, the severity of RPGN in WT recipient mice was substantial and was independent of the source of bone marrow, as albumin urinary excretion and crescent formation were similar in both groups (Supplementary Fig. 3e,f) , as was BUN concentration (data not shown). Thus, the cells responsible for producing pathophysiological HB-EGF are not of hematopoietic origin.
TGF-a-and epiregulin-deficient mice do not resist to RPGN Enhanced EGFR phosphorylation in the renal cortex in response to NTS was correlated with glomerular damage (Supplementary Fig. 4a ) and depended on HB-EGF, suggesting it is part of a nonredundant mechanism for EGFR activation and is directly implicated in crescent formation. We nevertheless addressed glomerular expression of alternative EGFR ligands, such as epiregulin (encoded by Ereg) and TGF-α. Without the availability of a suitable antibody to mouse epiregulin, we used Ereg promoter-driven lacZ expression in Ereg −/− mice as a monitoring tool for epiregulin expression in the kidney. As has been described earlier, we observed lacZ staining in punctuate patches throughout the digestive tract and in vascular smooth muscle cells 22 .
In contrast, we found no lacZ staining in glomeruli at baseline or after NTS administration (data not shown). We also assessed epiregulin antigen expression in kidney biopsies from subjects diagnosed with RPGN and found no epiregulin immunoreactivity in normal or crescentic glomeruli (Supplementary Fig. 4b,c) . Likewise, immunoreactive TGF-α was not found in experimental or in human RPGN ( Supplementary Fig. 4d ,e and data not shown). We nevertheless addressed the roles of epiregulin and TGF-α in the pathophysiology of experimental RPGN. Ten C57BL/6J, 10 TGF-α-deficient (wa1/wa1) and ten epiregulin-deficient Ereg −/− C57BL/6J males had similar renal histology and functional parameters (microalbuminuria, serum creatinine and BUN) at baseline (data not shown) and similar albuminuria levels and crescentic lesions in response to NTS ( Supplementary  Fig. 4f,g ). Thus, our results support a nonredundant role for HB-EGF in EGFR-driven aspects of RPGN pathogenesis.
Specific deletion of Egfr in podocytes prevents renal failure
To determine whether EGFR expression in podocytes in vivo is necessary for crescent formation and renal failure, we selectively deleted Egfr from renal podocytes. We used a conditional expression model (the Tet-on system) in which the target gene is deleted only in the presence of a tetracycline derivative to achieve temporal podocytespecific deletion of the Egfr gene in mice ( Supplementary Fig. 5a,b) . Mice of all genotypes were born at the expected Mendelian frequency and appeared healthy. At 10 weeks after doxycycline administration, kidney histology was normal (Supplementary Fig. 5c ), no apoptotic cells were observed in glomeruli ( Supplementary  Fig. 5d ) and albuminuria was within the physiological range (data not shown). Ten podocin-rtTA-Tet-O-Cre Egfr loxP/loxP males and 12 podocin-rtTA-Tet-O-Cre Egfr wt/wt gender-matched littermates were subjected to severe, life-threatening RPGN with a high dose of NTS. Podocyte-specific deletion of Egfr alleviated albumin urinary excretion (Fig. 4a) , the rise of BUN concentrations (Fig. 4b) and crescent formation (Fig. 4c) and completely protected mice from death (0% mortality versus 66% mortality for control mice with unperturbed EGFR expression in podocytes; Fig. 4d ). Greater kidney function and survival were also correlated with less severe changes to podocyte ultrastructure in tetracycline-induced podocinrtTA-Tet-O-Cre Egfr loxP/loxP mice relative to tetracycline-induced podocin-rtTA-Tet-O-Cre Egfr wt/wt littermate controls. More severe foot process effacement and irregular thickening of GBM was visible in Pod-Tet on-Cre Egfr wt/wt animals (Fig. 4e) .
Blockade of EGFR kinase prevents RPGN and renal failure
Together, our data suggested that HB-EGF-dependent activation of the EGFR in podocytes is important in crescent formation, albuminuria and renal failure. We therefore tested whether pharmacological inhibition of the EGFR pathway prevented renal damage. AG1478 is a synthetic inhibitor of EGFR autophosphorylation 23 . Daily intraperitoneal administration of AG1478 to WT mice not only prevented the EGFR phosphorylation observed in animals receiving vehicle control (Fig. 1c,d ) but also substantially reduced the development of crescentic lesions (AG1478 versus vehicle, n = 7 per group, P < 0.01; Supplementary Fig. 6a,b) and kept the distribution of CD3 + cells normal (Supplementary Fig. 6c,d) . AG1478 also reduced the severity of ascites (AG1478 versus vehicle, n = 7 per group, P < 0.01; Supplementary Fig. 6e ) and albuminuria (n = 7 per group, P < 0.01; Supplementary Fig. 6f ) and preserved renal function, as assessed by BUN (n = 6-7 per group, P < 0.05 for AG1478 versus vehicle and P = NS for AG1478 versus control; Supplementary Fig. 6g) . No AG1478-treated WT mouse died within 8 d of RPGN.
Delayed inhibition of the EGFR kinase stops RPGN
To determine whether inhibition of the EGFR pathway could represent a therapeutic option for RPGN, we administered a clinically available EGFR inhibitor, erlotinib, on day 4 after infusion of NTS. We chose this time point because it is when albuminuria and acute renal failure peak, and thus it is clinically relevant. We compared this regimen to the effect of vehicle alone and to the administration of erlotinib 12 h before the first infusion of NTS. The dose of erlotinib we used significantly inhibited EGFR phosphorylation (Fig. 5a) . Again, 'preventive' EGFR tyrosine kinase inhibition reduced the proportion of crescentic glomeruli (Fig. 5b) and alleviated the rise in BUN concentrations (Fig. 5c) . Erlotinib treatment also attenuated ultrastructural alterations of podocytes and full loss of interdigitating foot process pattern (Fig. 5d) . Overall, early and delayed administration of erlotinib had similar marked therapeutic effects on renal damage, inflammation and renal failure in our experimental model ( Fig. 5b-e) .
The EGFR pathway is not required for foot process effacement
To explore whether EGFR kinase activity has a direct role in regulating podocyte foot process structure and function, we next compared microalbuminuria, glomerular histopathology and foot process morphology of vehicle-or erlotinib-treated WT 129S2 mice before and after administration of lipopolysaccharide (LPS), a model that has been used to define the role of pathways important for the dynamic regulation of the podocyte cytoskeleton 24 . Morphologically, there was no difference between vehicle-and erlotinib-treated mice for any of these indices at baseline (data not shown). Moreover, after LPS injection, we found equal albuminuria and podocyte foot process effacement in mice treated with erlotinib or vehicle control (Supplementary Fig. 7a,b) . This is in agreement with the lack of induction of EGFR phosphorylation in glomeruli (Supplementary Fig. 7c ) and in the renal cortex ( Supplementary  Fig. 7d ) of LPS-injected mice in contrast with our observations during NTS-induced RPGN.
Phosphorylation levels of EGFR were similar upon LPS administration to those we observed at baseline in controls ( Supplementary  Fig. 7d ). These data indicate that intact EGFR tyrosine kinase activity is not mandatory for pathological urinary protein loss or effacement of podocyte foot processes and that different pathways cause RPGN and LPS-induced proteinuria.
High expression of HB-EGF in human kidneys with RPGN
To evaluate the relevance of these findings to human disease, we used immunostaining with three unrelated antibodies to human HB-EGF to address upregulation of HB-EGF in glomeruli from subjects with crescentic RPGN (Supplementary Fig. 8a ). All three antibodies showed similar patterns of HB-EGF labeling both in normal human kidney and in renal biopsies from subjects with RPGN (Supplementary Fig. 8a) . In normal human kidneys, HB-EGF labeling was weak and restricted to tubules and vascular smooth muscle cells (Supplementary Fig. 8a ). We found little or no epithelial expression of HB-EGF in glomeruli from subjects diagnosed with noncrescentic glomerulopathies (Fig. 6) . HB-EGF labeling in glomeruli from subjects with crescentic RPGN was substantially stronger overall, particularly in podocytes, parietal epithelial cells and tubules ( Fig. 6  and Supplementary Fig. 8b) . Moreover, HB-EGF staining was more intense and diffuse in glomeruli with crescents than in less affected glomeruli within the same tissue samples (Supplementary Fig. 8a ). We also observed weaker but consistent HB-EGF expression in inflammatory infiltrates (Supplementary Fig. 8b ). We observed a similar pattern of HB-EGF expression in all kidney samples with RPGN, regardless of the immunological cause ( Fig. 6 and Supplementary  Fig. 8b ). These studies show that HB-EGF is specifically increased, sometimes in a sustained fashion, in conditions associated with crescent formation and immune destruction of the glomeruli.
DISCUSSION
Our results are consistent with a pathogenic pathway of RPGN in which HB-EGF can be induced in the kidney to elicit EGFR activation primarily in podocytes, which in turn promotes glomerular lesions. Although this pathway has been delineated in an experimental mouse model of RPGN, immunolabeling of human kidney biopsies suggests that the pathway may be active in human disease. The gene encoding HB-EGF has enhanced expression in the kidneys of rats with streptozotocin-induced diabetes 25 and in models of membranous and minimal-change nephropathies 26 . Nevertheless, it had not been known whether EGFR phosphorylation is induced in these models and whether HB-EGF has any pathophysiological actions. In the puromycin aminonucleoside nephritis rat model, administration of affinity-purified monoclonal antibody to human HB-EGF induces earlier onset of albuminuria with no subsequent effect on renal function or other major renal endpoints 27 . On the basis of these reports, we addressed the role of HB-EGF in a severe and inflammatory model of renal damage reminiscent of human proliferative glomerulonephritis. Crescentic RPGN comprises the most severe class of glomerulopathies in humans and requires costly and immunosuppressive therapies prone to side effects 28, 29 . The inflammatory infiltrate in glomeruli and interstitium is composed of T lymphocytes, mononuclear phagocytes and neutrophils 11, 30 , as has been described in other animal models of crescentic glomerulonephritis and human RPGN 9, 19, [31] [32] [33] [34] [35] [36] . HB-EGF is rapidly induced in mesangial cells and glomerular epithelial cells in the anti-Thy-1.1 model of mesangial injury 37 . ProHB-EGF mRNA expression is induced in glomeruli of rats 30 min after administration of NTS, and contributes to acute glomerular hemodynamic alterations 2 ; however, this was a short-term study with no assessment of clinically relevant endpoints, such as renal damage, proteinuria and death. Indeed, upregulation of HB-EGF in this model decreased spontaneously to baseline by 24 h. Nevertheless, a clinical report of high mesangial expression of HB-EGF in a variety of human glomerulonephritis disorders suggests that HB-EGF is chronically induced in renal disease 38 . However, in our NTS model of severe glomerular injury, HB-EGF deficiency and EGFR blockade both prevent the development of ascites and renal leukocytic infiltrates before the appearance of patent crescentic proliferative lesions and interstitial fibrosis; therefore, we suggest that the HB-EGF-EGFR pathway acts very early to promote renal damage.
Several other cell types may participate in early HB-EGF release. HB-EGF has been reported in wound fluid 5 , macrophages 6 and T cell subsets in tumors and atherosclerotic plaques 7, 21 , although its functions in these settings are unknown. In a lupus model of accelerated crescentic glomerulonephritis, there is a marked and sustained increase in renal proHB-EGF mRNA, in part in macrophages 39 . Nevertheless, we observed that HB-EGF expression in interstitial inflammatory infiltrates is much weaker than within crescentic glomeruli in mouse and human kidney cortex. Accordingly, we found that immunolocalization of pEGFR shows a prominent distribution in glomeruli. Furthermore, deficiency of HB-EGF restricted to bone marrow-derived cells did not reduce the severity of experimental RPGN, in contrast with results obtained with systemic or podocytespecific alteration of the HB-EGF-EGFR pathway. Although these observations do not exclude the involvement of the HB-EGF-EGFR pathway in the early inflammatory phase of the disease, they suggest a prominent pathophysiological role for HB-EGF released by intrinsic renal cells, probably upon stimulation by immune mediators. Notably, residual podocyte alterations and albuminuria could still be measured in Hbegf −/− mice or after EGFR inhibition. This may occur because NTS can cause albuminuria through a direct noninflammatory effect on podocytes. For example, NTS has revealed several podocyte antigens such as aminopeptidase A 40 . These findings, in combination with previous studies showing that monoclonal antibodies to aminopeptidase A induce proteinuria in mice, suggest that some antibodies to aminopeptidase A may be responsible for complement-independent proteinuria in this model 40 .
Although other pathways must contribute to crescent formation, this is the first report, to our knowledge, to demonstrate a pathophysiological role for HB-EGF in a model of human disease and a role for EGFR in a model of renal immune-mediated destruction. By using a mouse genetic model of HB-EGF deficiency, we overcame the potential lack of specificity, affinity and bioavailability of neutralizing antibodies. Moreover, although HB-EGF is a growth factor, its observed actions seem to extend beyond its known mitogenic properties: HB-EGF-deficient mice were protected from inflammatory renal infiltration and albuminuria before the development of marked renal cell proliferation. We observed several hallmarks of altered cytoskeletal dynamics engaging the HB-EGF-EGFR axis in podocytes, such as RiLiSs formation (an assay for apical protrusions and apical migration) and migration. Notably, wound closure involves protrusion dynamics, cell polarity and cell-cell adhesion, but it seems to be largely independent of proliferation 18 . To confirm that these effects were not due to a developmental effect of chronic HB-EGF deficiency on the maturation of the immune system or of the kidney, we verified that podocyte-specific deletion in adult animals of the EGFR, the main receptor for HB-EGF, mimicked the phenotype induced by genetic targeting of the Hbegf gene.
Although downregulation of EGFR expression is associated with increased apoptosis in other cell types 41 , specific deletion of the EGFR in adult podocytes per se did not increase podocyte apoptosis or proteinuria. Moreover, inducible and specific deletion of the Egfr gene in adult podocytes significantly alleviated the course of fatal RPGN, indicating that the HB-EGF-EGFR pathway has a pathophysiological role in these cells in vivo. Induction of EGFR phosphorylation during disease progression and phenocopying of HB-EGF deficiency with EGFR deficiency suggests that activation of ErbB4, another receptor for HB-EGF that may promote distinct cellular effects 42 , has a marginal role, if any, in our model. Our results also show that EGFR was not highly phosphorylated in the renal cortex of HB-EGF-deficient mice after injection of NTS, implicating HB-EGF in EGFR activation in RPGN. Although we cannot exclude the possibility that other ligands in other kidney compartments may participate in RPGN progression, lack of protection from glomerulonephritis in NTS-challenged TGF-α-or epiregulin-deficient mice supports a nonredundant role for HB-EGF. Epiregulin was a potentially important target to investigate because its gene (Ereg) is induced by serum in quiescent human mesangial cells 43 . Furthermore, comprehensive expression profiling using an inducible WT1 expression model has identified Ereg, as well as Hbegf, as a direct WT1 target gene 44 . Only HB-EGF was unrepressed in crescentic RPGN, whereas WT1 was no longer expressed in pathological glomerular epithelial cells, suggesting that Hbegf is also controlled by WT1-independent pathways.
Use of an EGFR kinase inhibitor attenuates increased glomerular volume and tubular volume in diabetic rats 45 and in a diabetic rat (TGR(mRen-2)27) model with overactivation of the renin angiotensin system 46 . However, no specific activation of the EGFR and of EGFR ligands was described in these studies. Although no beneficial effect of EGFR inhibition on glomerulosclerosis or kidney failure was demonstrated in these studies, the results suggest that the EGFR pathway is involved in the control of glomerular hemodynamics 46 . In contrast, the findings do not seem relevant to the potential therapy we identified in aggressive proliferative glomerulonephritis.
Finally, the efficacy of two distinct EGFR inhibitors administered either shortly before NTS infusion or 4 d after the beginning of RPGN (that is, after preimmunization) suggests that recruitment of the HB-EGF-EGFR pathway is involved during the effector phase of the disease and does not have a substantial role in the preimmunization process. Accordingly, the humoral response was similar in HB-EGF-deficient and normal animals that had similar amounts of anti-sheep IgG.
In agreement with our measurement of induction of proHB-EGF mRNA expression in freshly sorted podocytes from nephritic mice ( Fig. 1b; Supplementary Methods) , we observed consistently more HB-EGF protein in glomeruli of human kidneys with crescentic RPGN than in normal tissues or in a variety of noncrescentic glomerular diseases. We observed expression of HB-EGF mainly in podocytes, parietal epithelial cells and tubules, a pattern similar to that reported in rat models of focal adhesive glomerular sclerosis or passive Heymann nephritis, although no strong chronic upregulation has been observed nAture medicine VOLUME 17 | NUMBER 10 | OCTOBER 2011 1 2 4 9 in these models 47 . Notably, in the same renal biopsies, the most severely affected glomeruli showed the most intense staining to HB-EGF in podocytes, further implicating HB-EGF in the pathophysiology of human RPGN. Furthermore, some kidney biopsies from individuals whose RPGN relapsed despite chronic immunosuppressive therapy showed sustained glomerular elevation of HB-EGF expression, again consistent with a specific role for this mediator.
In conclusion, the data presented here provide evidence that immune-mediated glomerular injury leads to active and sustained pathophysiological recruitment of glomerular EGFR by HB-EGF. In contrast to reports suggesting a protective or a negligible role for HB-EGF in models of mild glomerular injury 2,27 , we demonstrate here that activation of EGFR in podocytes is involved in a severe form of glomerular injury that leads to death from renal failure. These findings raise the possibility that specific EGFR inhibitors may be of therapeutic value for treating crescentic and other types of inflammatory glomerulonephritis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
